September 24, 2021
Company Info
| Industry | Pharmaceuticals: Generic |
|---|---|
| Sector | Health Technology |
| Employees | 39,717 |
| CEO | Mr. Kåre Schultz |
| Address | 5 Basel Street , Petach Tikva, HM 4951033 |
|---|---|
| Phone | 972.3.926.7267 |
| Website | www.teva.co.il |
Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.
Competitors
| Company Name | 3 Month %Change |
1 Year %Change |
|---|---|---|
| Teva Pharmaceutical Industries Ltd. | -11.27% | 3.47% |
| Hill-Rom Holdings, Inc. | 34.49% | 82.33% |
| Acceleron Pharma, Inc. | 30.81% | 53.77% |
| United Therapeutics Corp. | 14.79% | 94.09% |
| CRISPR Therapeutics AG | -7.22% | 37.59% |
Statement Summary
as of 4:10 ET PM 09/23/2021| Total Assets (MRQ) | 49.2 B |
|---|---|
| Total Liabilities (MRQ) | 37.9 B |
| Shareholders’ Equity (MRQ) | 11.3 B |
| Total Revenue (Annual) | 3.9 B |
| Net Income (Annual) | 207.0 M |
Earnings And Estimates
as of 4:10 ET PM 09/23/2021
| Current Qtr EPS Estimate | 0.65 |
|---|---|
| Current FY EPS Estimate | 2.60 |
| Long Term EPS Growth Estimate | 4.02 |
| Next Expected Earnings Date | // |
TEVA vs S&P 500
as of 09/23/2021| Relative To S&P 500 |
TEVA | |
|---|---|---|
| 4 Weeks | n/a | n/a |
| 12 Weeks | n/a | n/a |
| YTD | n/a | n/a |
Earnings Surprises
as of 4:10 ET PM 09/23/2021| Fiscal Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 06/2021 | 0.59 | 0.59 | -0.40% |
| 03/2021 | 0.59 | 0.63 | +6.64% |
| 12/2020 | 0.63 | 0.68 | +8.23% |
| 09/2020 | 0.58 | 0.58 | -0.36% |
| 06/2020 | 0.53 | 0.55 | +4.62% |
| 03/2020 | 0.59 | 0.76 | +28.45% |
| 12/2019 | 0.61 | 0.62 | +2.28% |
| 09/2019 | 0.59 | 0.58 | -2.03% |
Financial Strength
as of 4:10 ET PM 09/23/2021| Pre-Tax Margin | 7.85 |
|---|---|
| Net Margin | 45.03 |
| Operating Margin | 19.95 |
| Return On Equity | -32.38 |
| Return On Assets | -7.51 |
| Inventory Turnover (TTM) | 1.99 |
| Sales Growth (MRQ) | -3.22 |
Ratios
as of 4:10 PM ET 09/23/2021| Price/Earnings (TTM) | n/a |
|---|---|
| Price/Book (MRQ) | 0.97 |
| Price/Cash Flow (TTM) | 5.10 |
| Book Value (MRQ) | 9.36 |
| Quick Ratio (MRQ) | 0.67 |
| Current Ratio (MRQ) | 1.01 |
| Total Debt/Equity (MRQ) | 2.48 |
Short Interest
as of 2:35 PM ET 09/24/2021| % Short - 2.11% | |
| % Remaining Float - 97.89% |
| Current | Last Month | |
|---|---|---|
| Short Interest Date | 08/31/2021 | 08/13/2021 |
| Short Interest Shares | 23,285,202 | 28,525,859 |
| Short Interest Ratio | 4.0 | 3.8 |
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00
0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00
0,0.00
Cash from
Activities
0,0.00
0,0.00
Cash from
Fin. Activities
0,0.00
0,0.00
TOTAL ASSETS |
TOTAL LIABILITIES |
TOTAL EQUITY |
|---|---|---|
Balance Sheet
| M Y | ||||
|---|---|---|---|---|
| ASSETS | ||||
| Cash And Equivalents | 0,0.00 | |||
| Receivables | 0,0.00 | |||
| Inventories | 0,0.00 | |||
| Other Current Assets | 0,0.00 | |||
| Total Current Assets | 0,0.00 | |||
| Property, Plant & Equipment, Gross | 0,0.00 | |||
| Accumulated Depreciation & Depletion | 0,0.00 | |||
| Property, Plant & Equipment, Net | 0,0.00 | |||
| Intangibles | 0,0.00 | |||
| Other Non-Current Assets | 0,0.00 | |||
| Total Non-Current Assets | 0,0.00 | |||
| TOTAL ASSETS | 0,0.00 | |||
| Liabilities & Shareholder Equity | ||||
| Accounts Payable | 0,0.00 | |||
| Short Term Debt | 0,0.00 | |||
| Total Current Liabilities | 0,0.00 | |||
| Long Term Debt | 0,0.00 | |||
| Deferred Income Taxes | 0,0.00 | |||
| Other Non-Current Liabilities | 0,0.00 | |||
| Minority Interest | 0,0.00 | |||
| Total Non-Current Liabilities | 0,0.00 | |||
| Preferred Stock Equity | 0,0.00 | |||
| Common Stock Equity | 0,0.00 | |||
| Common Par | 0,0.00 | |||
| Additional Paid In Capital | 0,0.00 | |||
| Cumulative Translation Adjustment | 0,0.00 | |||
| Retained Earnings | 0,0.00 | |||
| Treasury Stock | 0,0.00 | |||
| Other Equity Adjustments | 0,0.00 | |||
| Total Capitalization | 0,0.00 | |||
| TOTAL EQUITY | 0,0.00 | |||
| TOTAL LIABILITIES & STOCK EQUITY | 0,0.00 | |||
| Total Common Shares Outstanding | 0,0.00 | |||
| Preferred Shares | 0,0.00 | |||
| Treasury Shares | 0,0.00 | |||
| Basic Weighted Shares Outstanding | 0,0.00 | |||
| Diluted Weighted Shares Outstanding | 0,0.00 | |||
| Number Of Employees | 0,0.00 | |||
| Number Of Part-Time Employees | 0,0.00 | |||
TOTAL REVENUES |
EBT Excluding Unusual Items |
NET INCOME |
|---|---|---|
Income Statement
| M Y | |
|---|---|
| Sales | 0,0.00 |
| Cost Of Sales | 0,0.00 |
| Gross Operating Profit | 0,0.00 |
| Selling, General, And Administrative Expenses | 0,0.00 |
| Research & Development | 0,0.00 |
| Operating Income Before D & A (EBITDA) | 0,0.00 |
| Depreciation & Amortization | 0,0.00 |
| Interest Income | 0,0.00 |
| Other Income - Net | 0,0.00 |
| Special Income / Charges | 0,0.00 |
| Total Income Before Interest Expenses (EBIT) | 0,0.00 |
| Interest Expense | 0,0.00 |
| Pre-Tax Income | 0,0.00 |
| Income Taxes | 0,0.00 |
| Minority Interest | 0,0.00 |
| Net Income From Continuing Operations | 0,0.00 |
| Net Income From Discontinued Operations | 0,0.00 |
| Net Income From Total Operations | 0,0.00 |
| Extraordinary Income/Losses | 0,0.00 |
| Income From Cum. Effect Of Acct. Change | 0,0.00 |
| Income From Tax Loss Carryforward | 0,0.00 |
| Other Gains / Losses | 0,0.00 |
| Total Net Income | 0,0.00 |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Preferred Dividends | 0,0.00 |
| Net Income Available To Common | 0,0.00 |
| Basic EPS From Continuing Ops. | 0,0.00 |
| Basic EPS From Discontinued Ops. | 0,0.00 |
| Basic EPS From Total Operations | 0,0.00 |
| Basic EPS From Extraordinary Inc. | 0,0.00 |
| Basic EPS From Cum Effect Of Accounting Change | 0,0.00 |
| Basic EPS From Tax Loss Carryf'd. | 0,0.00 |
| Basic EPS From Other Gains (Losses) | 0,0.00 |
| Basic EPS, Total | 0,0.00 |
| Basic Normalized Net Income/Share | 0,0.00 |
| EPS From Continuing Ops. | 0,0.00 |
| EPS From Discontinued Ops | 0,0.00 |
| EPS From Total Ops. | 0,0.00 |
| EPS From Extraord. Inc. | 0,0.00 |
| EPS From Cum Effect of Accounting Change | 0,0.00 |
| EPS From Tax Loss Carfd. | 0,0.00 |
| EPS From Other Gains (L) | 0,0.00 |
| EPS, Total | 0,0.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0,0.00 |
| Dividends Paid Per Share | 0,0.00 |
CASH FROM OPERATIONS |
CASH FROM INVESTING ACTIVITIES |
CASH FROM FINANCING ACTIVITIES |
|---|---|---|
Cash Flow Statement
| M Y | ||||
|---|---|---|---|---|
| Cash Flow From Operating Activities | ||||
| Net Income (Loss) | 0,0.00 | |||
| Operating Gains/Losses | 0,0.00 | |||
| Gross Operating Profit | 0,0.00 | |||
| (Increase) Decrease In Receivables | 0,0.00 | |||
| (Increase) Decrease In Inventories | 0,0.00 | |||
| (Increase) Decrease In Other Current Assets | 0,0.00 | |||
| (Decrease) Increase In Other Current Liabilities | 0,0.00 | |||
| (Increase) Decrease In Other Working Capital | 0,0.00 | |||
| Other Non-Cash Items | 0,0.00 | |||
| Net Cash From Continuing Operations | 0,0.00 | |||
| Net Cash From Discontinued Operations | 0,0.00 | |||
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 0,0.00 | |||
| Sale Of Property, Plant & Equipment | 0,0.00 | |||
| Cash Used For Investing Activities | ||||
| Sale Of Short-Term Investments | 0,0.00 | |||
| Purchases Of Property, Plant & Equipment | 0,0.00 | |||
| Acquisitions | 0,0.00 | |||
| Purchases Of Short-Term Investments | 0,0.00 | |||
| Other Cash From Investing Activities | 0,0.00 | |||
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 0,0.00 | |||
| Issuance Of Debt | 0,0.00 | |||
| Cash Used For Financing Activities | ||||
| Issuance Of Capital Stock | 0,0.00 | |||
| Repayment Of Long-Term Debt | 0,0.00 | |||
| Repurchase Of Capital Stock | 0,0.00 | |||
| Payment Of Cash Dividends | 0,0.00 | |||
| Other Financing Charges, Net | 0,0.00 | |||
| Net Cash From Financing Activities | 0,0.00 | |||
| Effect Of Exchange Rate Changes | 0,0.00 | |||
| Net Change In Cash & Cash Equivalents | 0,0.00 | |||
Earnings Estimates
as of 4:10 ET PM 09/23/2021| Current Qtr (09/2021) |
Next Qtr (12/2021) |
|
|---|---|---|
| Consensus Estimate | $0.65 | $0.73 |
| # of Estimates | 14 | 13 |
| High Estimate | $0.68 | $0.80 |
| Low Estimate | $0.62 | $0.67 |
| Year Ago EPS | $-3.97 | $0.14 |
| Year Over Year Growth Estimate | -116.26% | 433.37% |
| Current Yr (12/2021) |
Next Yr (12/2022) |
|
|---|---|---|
| Consensus Estimate | $2.60 | $2.74 |
| # of Estimates | 15 | 15 |
| High Estimate | $2.70 | $2.80 |
| Low Estimate | $2.53 | $2.59 |
| Year Ago EPS | $2.57 | $2.60 |
| Year Over Year Growth Estimate | 1.34% | 5.11% |
| Current Qtr (09/2021) |
Next Qtr (12/2021) |
Current Year (12/2021) |
Next Year (12/2022) |
|
|---|---|---|---|---|
| Consensus Estimate | $0.65 | $0.73 | $2.60 | $2.74 |
| # of Estimates | 14 | 13 | 15 | 15 |
| High Estimate | $0.68 | $0.80 | $2.70 | $2.80 |
| Low Estimate | $0.62 | $0.67 | $2.53 | $2.59 |
| Year Ago EPS | $-3.97 | $0.14 | $2.57 | $2.60 |
| Year Over Year Growth Estimate | -116.26% | 433.37% | 1.34% | 5.11% |
Insider Information Summary
as of 08/31/2021| % Insiders - 0.01% | |
| % Remaining Total Shares - 99.99% |
| Current | 1 Month | |
|---|---|---|
| Net Insider Transaction | 0.00 | 0.00 |
| Shares Bought | 0.00 | 0.00 |
| Shares Sold | 0.00 | 0.00 |
Insider Activity
| Transaction Date | Insider/Title | Transaction Type | Market Value | Shares | Average Price | Current Holdings | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
LATEST NEWS
Endo International Stock Jumps on $50M Opioid-Claim Accord
Sep 10, 2021 11:07 AM EDT
Latest News
5 Top Stock Gainers for Wednesday: Tilray, Boeing and Alphabet
Jul 28, 2021 4:35 PM EDT
Teva Announces Changes To Executive Management Team
Jul 21, 2021 8:00 AM EDT
Teva And Bioeq Announce Commercial Partnership For Biosimilar
Jun 28, 2021 8:00 AM EDT
Teva Halts Search for Partners to Develop COVID-19 Vaccine
Apr 28, 2021 2:47 PM EDT
Recent Articles from TheStreet
Jim Cramer is Tired of the Weak Response to Chip Shortages
Companies need to forget about help from Washington and step up to the plate.
Why 'Sarge' Guilfoyle Isn't Selling His Microsoft
Sharp management and strength across its business lines are keys to software giant.
Bret Jensen: Paratek Deal Shows Promise
While antibiotics are usually less profitable and slower to develop market share than other drugs, Paratek has a key factor in its favor.
Dow Higher Amid Evergrande Default Saga, Supply Chain Chaos
Evergrande's default saga, as well as mounting supply chain issues, have stocks trading mixed Friday.
Stock Market Today With Jim Cramer: China's Crypto Clampdown
Jim Cramer discusses China's crypto clampdown and Nike's report.
Carnival Climbs on Positive Q3 Results, Outlook
Carnival says it was cash flow positive in the third quarter and expects that trend to continue into the end of the year.
American Air Pilots Call for Operations Managers to be Ousted
The American pilots union called out the managers for delays and cancellations that have affected thousands of customers this year.
5 Top Stock Gainers for Friday: Meredith, Costco, Vail Resorts
Meredith, Costco, Vail Resorts, Progress Software and BJ's Restaurants are five top stock gainers for Friday.
How to Trade Ethereum After China's Ban on Crypto Trading
Ethereum and other cryptocurrencies are under intense stress. Here's how to trade it until the larger range resolves.
Vornado, SL Green Shares Rise; Bank of America Touts Tech Growth
Shares of office REIT titans Vornado and SL Green rose Friday after Bank of America upgraded them to neutral.
CLOSE
CLOSE
CLOSE
CLOSE